Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. While the introduction of direct-acting antiviral therapies which can cure HCV in the majority of patients represents a major advance, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.

This podcast aims to empower GPs to recognise the different ways in which stigma related to HCV infection can present in the primary care setting and consider communication techniques and tools to help overcome this – thereby optimising outcomes for patient with HCV infection.

Dr Tom Dover explains the new indication for dulaglutide (adjunct to standard of care to reduce the risk of MACE in T2D patients with established CVD OR multiple CVD risk factors) in the context of recent Australian and international guideline recommendations to consider CVD risk when selecting glucose lowering therapies. Practical implications for Australian GPs are discussed.

This podcast aims to empower GPs to diagnose and adopt best practice management of migraines to improve quality of life and functional outcomes for patients.

This podcast aims to empower GPs to diagnose and adopt best practice management of migraines to improve quality of life and functional outcomes for patients.

This podcast aims to empower GPs to diagnose and adopt best practice management of migraines to improve quality of life and functional outcomes for patients. It features two cases studies and expert video interviews from the faculty. 

This podcast will have Gastroenterologist discussing key clinical issues around IDA and the role of high-dose iron management. With practical cases being considered and why is iron replacement a low priority?  

At the end of this Podcast GP's will be able to identify the features that distinguish migraine from headache and other neurological ‘red flags’, and instances in which patients should be referred for specialist investigation and management. 

Professor Ken O’Byrne and Dr Robert Zielinski discuss the highlights from ESMO Barcelona 2019 on the management of advanced lung cancer management and what this means for Australian Oncologists.

Professor Chris Karapetis and Professor Julien Taieb discuss international perspective on Lonsurf – a novel third line alternative for metastatic colorectal cancer.